Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101


Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens.

Wang S, Shi Y, Yuan Z, Wang X, Liu D, Peng R, Teng X, Qin T, Peng J, Lin G, Jiang X.

Med Oncol. 2012 Jun;29(2):547-53. doi: 10.1007/s12032-011-9964-2. Epub 2011 Apr 29.


Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart M, Pritchard K.

Lancet. 2012 Feb 4;379(9814):432-44. doi: 10.1016/S0140-6736(11)61625-5. Epub 2011 Dec 5.


Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG).

Lancet. 2005 May 14-20;365(9472):1687-717.


Adjuvant chemotherapy in early breast cancer.

Ejlertsen B.

Dan Med J. 2016 May;63(5). pii: B5222. Review.


HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, O'Malley FP, Cardoso F, Tanner M, Munro A, Twelves CJ, Sotiriou C, Shepherd L, Cameron D, Piccart MJ, Buyse M; HER2/TOP2A Meta-analysis Study Group.

Lancet Oncol. 2011 Nov;12(12):1134-42. doi: 10.1016/S1470-2045(11)70231-5. Epub 2011 Sep 12.


Selection of adjuvant chemotherapy for treatment of node-positive breast cancer.

Trudeau M, Charbonneau F, Gelmon K, Laing K, Latreille J, Mackey J, McLeod D, Pritchard K, Provencher L, Verma S.

Lancet Oncol. 2005 Nov;6(11):886-98. Review.


Comparison of three adjuvant chemotherapy regimes using an extended log-logistic model in women with operable breast cancer.

Faradmal J, Kazemnejad A, Khodabakhshi R, Gohari MR, Hajizadeh E.

Asian Pac J Cancer Prev. 2010;11(2):353-8.


Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.

Martin M, Villar A, Sole-Calvo A, Gonzalez R, Massuti B, Lizon J, Camps C, Carrato A, Casado A, Candel MT, Albanell J, Aranda J, Munarriz B, Campbell J, Diaz-Rubio E; GEICAM Group (Spanish Breast Cancer Research Group), Spain.

Ann Oncol. 2003 Jun;14(6):833-42. Review.


HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15.

Paik S, Bryant J, Tan-Chiu E, Yothers G, Park C, Wickerham DL, Wolmark N.

J Natl Cancer Inst. 2000 Dec 20;92(24):1991-8.


Primary chemotherapy in operable breast carcinoma comparing CMF (cyclophosphamide, methotrexate, 5-fluorouracil) with an anthracycline-containing regimen: short-term responses translated into long-term outcomes.

Cocconi G, Di Blasio B, Boni C, Bisagni G, Rondini E, Bella MA, Leonardi F, Savoldi L, Vallisneri C, Camisa R, Bruzzi P; Italian Oncology Group for Clinical Research (GOIRC), Parma, Italy.

Ann Oncol. 2005 Sep;16(9):1469-76. Epub 2005 Jun 14.


Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial.

Cheang MC, Voduc KD, Tu D, Jiang S, Leung S, Chia SK, Shepherd LE, Levine MN, Pritchard KI, Davies S, Stijleman IJ, Davis C, Ebbert MT, Parker JS, Ellis MJ, Bernard PS, Perou CM, Nielsen TO.

Clin Cancer Res. 2012 Apr 15;18(8):2402-12. doi: 10.1158/1078-0432.CCR-11-2956. Epub 2012 Feb 20.


Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy.

Bozovic-Spasojevic I, Ameye L, Paesmans M, Larsimont D, Di Leo A, Dolci S, Piccart M, de Azambuja E, Loi S.

Breast. 2014 Aug;23(4):473-81. doi: 10.1016/j.breast.2014.03.012. Epub 2014 Apr 24.


Concurrent chemoradiotherapy in adjuvant treatment of breast cancer.

Ismaili N, Mellas N, Masbah O, Elmajjaoui S, Arifi S, Bekkouch I, Ahid S, Bazid Z, Tazi MA, Erraki A, El Mesbahi O, Benjaafar N, El Gueddari Bel K, Ismaili M, Afqir S, Errihani H.

Radiat Oncol. 2009 Apr 7;4:12. doi: 10.1186/1748-717X-4-12.


The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses.

Campbell HE, Epstein D, Bloomfield D, Griffin S, Manca A, Yarnold J, Bliss J, Johnson L, Earl H, Poole C, Hiller L, Dunn J, Hopwood P, Barrett-Lee P, Ellis P, Cameron D, Harris AL, Gray AM, Sculpher MJ.

Eur J Cancer. 2011 Nov;47(17):2517-30. doi: 10.1016/j.ejca.2011.06.019. Epub 2011 Jul 7.


Supplemental Content

Support Center